Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04547439 · ClinicalTrials.gov registry record · Phase 2

Sleep, Diabetic Retinopathy and Melatonin

A Phase 2 study of Diabetes Mellitus and Diabetic Retinopathy, sponsored by University of Illinois at Chicago.

Recruiting
Registry status
Phase 2
Development phase
42
Enrollment target
1
Study location

NCT04547439: Recruiting Phase 2 study of Diabetes Mellitus and Diabetic Retinopathy, sponsored by University of Illinois at Chicago.

NCT04547439 is a Phase 2 study of Diabetes Mellitus and Diabetic Retinopathy that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 42 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04547439, a Phase 2 study of Diabetes Mellitus and Diabetic Retinopathy, is actively recruiting participants, sponsored by University of Illinois at Chicago.

RECRUITING
Registry status
Phase 2
Development phase
42 participants
Enrollment target
1
Study location

Study Summary

This study explores the use of melatonin in patients with diabetic retinopathy

Primary Outcome

Sleep pattern: Sleep duration and sleep efficiency will be assessed by wrist actigraphy, to be worn by the participants for 14 days

Conditions Studied

Diabetes Mellitus Diabetic Retinopathy

Interventions

  • OTHER Placebo
  • DRUG Melatonin

Study Locations (1)

Illinois

  • University of Illinois at Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2021-02-03
Est. Completion 2026-06
Phase Phase 2
University of Illinois at Chicago

430 total trials

What NCT04547439 shows while recruiting

NCT04547439 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04547439 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT04547439 about?

NCT04547439 is a clinical study titled "Sleep, Diabetic Retinopathy and Melatonin". This study explores the use of melatonin in patients with diabetic retinopathy

What is the current status of trial NCT04547439?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2021-02-03. Estimated completion is 2026-06.

What conditions does trial NCT04547439 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Diabetic Retinopathy.

What interventions are being tested in trial NCT04547439?

The interventions under investigation include: Placebo (OTHER), Melatonin (DRUG).

Who is sponsoring clinical trial NCT04547439?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04547439 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04547439's enrollment target sits among peer trials

42 161st of 208 higher than 48 of 208 other Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04547439

Source: ClinicalTrials.gov NCT04547439, the US trial registry maintained by the National Library of Medicine. NCT04547439 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.